Medherant logo

Medherant is developing a pipeline of products for pain and neurology indications, based on our next-generation TEPI-Patch® transdermal drug technology. Our first product ‐ Ibuprofen TEPI Patch ‐ entered the clinic in 2018.

Key advantages of the TEPI Patch® technology over current technologies are the high payload and very efficient release of drug. This enables lower potency drugs to be formulated as a patch and provides the opportunity to increase the dose of drugs already administered via a patch whilst also minimising the residual drug after use.

The TEPI Patch® also provides a better experience for the user as it does not leave a residue around the patch ‐ referred to as ‘cold flow’ ‐ and has excellent adhesion whilst still being easy and painless to remove. No organic solvents are involved in this drug-in-adhesive system.

As well as developing our own products, Medherant offers pharma companies rapid feasibility studies using our proprietary high throughput permeation study system to develop transdermal formulations of their drugs of interest.

Contact Medherant via their website

News archive

04/06/2020   Cycle Pharmaceuticals and Medherant Announce Agreement...more

23/09/2019   Medherant named in 50 most innovative businesses in the Midlands...more
25/06/2019   Medherant positions for the next stage of development with the appointment of new CEO...more
21/05/2019   Mercia invests £2.0 million in transdermal drug delivery specialist, Medherant...more
02/03/2019   Meet Medherant at Sachs CEO Forum and BIO-Europe Spring...more
11/02/2019   Medherant included in Silicone Republic Europe Start-up 100...more

05/11/2018   Medherant announces positive phase 1 results...more
03/10/2018   Medherant Awarded Innovate UK Medicines Manufacturing Grant...more
11/09/2018   Medherant nominated for two CPhI Pharma Awards...more
06/06/2018   Medherant Patch up the pain: A case study in transdermal drug delivery...more
07/03/2018   Medherant appoints new Head of Development...more
14/02/2018   Medherant article published in Innovations in Pharmaceutical Technology...more

18/12/2017   Medherant published in Journal of Pharmaceutical Innovation...more
11/12/2017   Medherant completes £3.8 million funding round...more
27/09/2017   Medherant signs agreement with Japanese transdermal patch company...more
26/06/2017   Medherant expands management team with appointment of new COO and CFO...more
12/06/2017   Medherant shortlisted for RSC Emerging Technologies competition...more
06/06/2017   Medherant appoints Sheryl Caswell as Head of Clinical Development...more
08/05/2017   Medherant Appoints its Transdermal Drug Delivery Patch Manufacturer...more
06/02/2017   Medherant Announces Appointment of New Chair...more
27/01/2017   Meet Medherant at 10th Annual European Life Sciences CEO Forum...more

27/09/2016   Medherant Completes £1.5M Fundraising for Transdermal Drug Delivery Platform...more
08/07/2016   Medherant shortlisted for ON Helix BioNewsRound 2016 Award...more
13/06/2016   Medherant Selected as an ON Helix BioNewsRound Award Finalist...more
05/05/2016   Mercia Makes Follow-On Investment In Medherant's Novel Transdermal Technology...more
22/02/2016   Medherant on Thomson Reuters TV...more
01/02/2016   Interview with Mercia and Medherant by MedNous...more
21/01/2016   Medherant Ltd joins the BioPartner programme...more

18/12/2015   Medherant's first ibuprofen patch - TEPI patch technology...more
02/06/2015   Medherant Announces Agreement with Bostik and Seed Investment Secured...more

The BioPartner Programme

BPP members enjoy our full range of discounts, enhanced promotion on BioPartner UK Delegations and first refusal on new international opportunities.

Not a member? Join the BioPartnership Programme

BioPartner UK is a member of

Sponsors Alliance

Prompt Payment Code